Recruiting

Testing a new immune therapy combined with chemotherapy and radiation for advanced lung cancer

Plain-English translation of NCT07138755 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination treatment for people with stage III non-small cell lung cancer (a type of lung cancer that cannot be surgically removed). The study combines three approaches: sintilimab, a medication that helps your immune system fight cancer; platinum-based chemotherapy drugs; and a specialized radiation therapy. Researchers want to see if this three-part approach works better and is safe for patients like you.

Stage III lung cancer is serious and difficult to treat, especially when surgery isn't an option. This medication works by "waking up" your immune system to recognize and attack cancer cells, and researchers believe combining it with chemotherapy and targeted radiation may give patients a better chance of beating the disease.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with stage III non-small cell lung cancer that cannot be removed by surgery
you have not received chemotherapy or chest radiation before
you have at least one measurable tumor that can be clearly tracked on imaging
your organs are healthy enough to tolerate this combination treatment
you do not have certain genetic mutations in your cancer (like EGFR, ALK, or ROS1)

You likely don't qualify if…

you have had another cancer diagnosis in the past 5 years (except for skin cancer or early-stage cancers that were completely treated)
you have an active autoimmune disease or are taking immune-suppressing medications
you have a history of a serious lung disease (non-infectious pneumonia or interstitial lung disease) that required steroids
you have had a serious infection in the past 4 weeks, including sepsis or severe pneumonia
you are living with HIV, hepatitis B, active tuberculosis, or active syphilis

What participation looks like

You would receive two cycles of sintilimab and chemotherapy first, followed by two additional cycles of the same medications combined with adaptive radiotherapy (a type of radiation that adjusts to your tumor as it shrinks). The study involves regular hospital visits for infusions, scans to measure your tumor, and blood tests to monitor how you're responding and check for side effects. The trial is enrolling 35 people total at a hospital in China.

AI-generated summary from trial data · Jul 3, 2026 · Not medical advice

Trial locations(4 sites)

China

Hunan Cancer Hospital, Changsha, Hunan

Xiangya 3rd Hospital, Central South University, Changsha, Hunan

The First Affiliated Hospital of Nanhua University, Hengyang, Hunan

Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital, Jishou, Hunan